Insys Therapeutics (INSY) Tops Q4 EPS by 7c

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $91.1 million versus the consensus estimate of $91.04 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period